Rush University Medical Center has once again been named one of the nation’s top hospitals, according to the upcoming issue of U.S. News & World Report. Rush is ranked in nine of 16 categories included in the magazine’s 2013-14 America’s Best Hospitals issue and is the second-ranked hospital in Illinois.
Just 147 of the approximately 5,000 hospitals in the United States — approximately 3 percent — scored high enough this year to rank in even one specialty nationally by U.S. News.
Rush’s ranked programs are orthopedics (No. 10 in the country); geriatrics (No. 12); neurology and neurosurgery (No. 16); urology (No. 25); heart and heart surgery (No. 28); nephrology (No. 30); diabetes and endocrinology (No. 35); pulmonology (No. 37); and gastroenterology (No. 41).
U.S. News also noted that the following Rush specialty services are “high-performing”: cancer; ear, nose and throat; gynecology; and psychiatry. Also, in June U.S. News‘ 2013-14 Best Children’s Hospitals list ranked Rush Children’s Hospital 40th in the country in gastroenterology.
“Rush continues to do great work in a broad spectrum of categories, and these rankings are representative of the outstanding quality of care provided at Rush,” said Dr. Larry J. Goodman, CEO, Rush University Medical Center. “Rush has earned its place among the top academic medical centers in America.”
Read the entire news release.
(CHICAGO) – Rush University Medical Center has been recognized as a Leader in LGBT Healthcare Equality in the Healthcare Equality Index report for the fifth consecutive year.
The HEI Index is an annual survey of U.S. health care facilities regarding treatment of lesbian, gay, bisexual and transgender patients and their families as well as their own employees. The 2013 report was released on July 11.
Rush is one of a select group of 464 health care facilities nationwide to be named Leaders in LGBT Healthcare Equality. Those awarded this title must meet key criteria for equitable treatment, including nondiscrimination policies for LGBT patients and employees; visitation policies that grant same-sex partners and parents the same access as different-sex partners and parents; and training in LGBT patient-centered care for key staff.
AAHRPP accredits organizations that meet rigorous research standards.
Rush University Medical Center received a renewal in June of its accreditation from the Association for the Accreditation of Human Research Protection Programs (AAHRPP).
AAHRPP accredits organizations conducting human research that can demonstrate that their research meets rigorous standards for ethics, quality and protections, exceeding the safeguards required by the U.S. government. Last year, Rush became one of the first academic medical centers in Illinois to receive the accreditation. Accreditations last three years, but institutions need to produce an annual research report annually to continue accreditation.
“The accreditation provides an important external endorsement — that Rush’s approach to research meets national best practices,” said Dr. Larry Goodman, Rush CEO. “While many organizations meet government regulations regarding participant safety and welfare, Rush has met a higher standard, set by our peers in the national research community.”
AAHRPP was established as a not-for-profit following a mandate from the Institute of Medicine to build public trust in clinical research. Rush is one of 184 other leading research institutions in having earned AAHRPP’s accreditation, which has emerged as the gold standard worldwide for clinical research quality.
Read the entire news release.
Every time a participant takes the entire dose in the correct time window, they will score points in a virtual game (i.e., the participant scores a basket in a basketball game each time they take a dose), and they earn 50 cents that they can use at the Googleplay store to purchase music, apps, movies or television shows.
Researchers at Rush University Medical Center are using multimedia coupled with positive reinforcement via a cell phone application to try to improve asthma outcomes among low-income, minority adolescents with asthma.
Each participant in the study receives a smartphone preloaded with an application that uses a reward system to encourage teenagers to proactively take their daily asthma controller medications. They also receive a free data plan (including unlimited talking, texting, email and Internet) for the duration of their participation in the study. The study is funded by the National Institutes of Health.
“Adolescents love technology. They spend an enormous amount of time listening to music and playing videogames, as well as using computers and mobile phones. We believe that leveraging existing use of technology would be a great way to engage adolescents and motivate them to taking their medication,” said Dr. Giselle Mosnaim, an allergy and immunology specialist at Rush University Medical Center.
Some asthma patients need to use daily controller medications to prevent asthma symptoms and attacks. Without the medication, a serious breathing problem can result due to inflammation in the airways. This may lead to missed school days or visits to the emergency room.
The Rush Fetal and Neonatal Medicine Center is hosting a drive for clothing, toiletries, toys and other such items for the Women’s Treatment Center on Chicago’s Near West Side. The Women’s Treatment Center is the only substance abuse treatment center in the state focused solely on women and specializing in treatment that is framed and informed by women’s issues.
“Many of these women are homeless or close to homeless,” said Jessica Cherikos, DNP, nurse practitioner, Rush Fetal and Neonatal Medicine Center. Cherikos provides prenatal care for many of these pregnant women who receive inpatient drug rehabilitation at the center.
“It is our role to care for their unborn child as well as the mother,” she said. “These women want the opportunity to change their lives and be great mothers. That is extremely difficult when they have almost no means to provide even the basics for their children. Often, the women and children admitted to the center have no possessions.”
Dr. Lydia Usha, director of the Rush Inherited Susceptibility to Cancer (RISC) program at Rush, is currently investigating genetic causes of cancer in patients who tested negative for the BRCA1 and BRCA2 genetic mutations but still developed breast or ovarian cancer and have a known mutation in one of these genes in the family.
The results may help explain why patients who test negative for a genetic predisposition to cancer may still develop cancer. Usha is examining the idea that certain people have the familial BRCA mutation in some tissues, but not in their blood. She hypothesizes that these patients have had BRCA-positive chimeric cells in their body since birth, making these cells more susceptible to developing cancer. Usha and her team are recruiting patients and testing their cancer tissue for the familial mutation.
“This is important because we know that some drugs are more effective in treating patients who have breast and ovarian cancers with these specific mutations,” Usha said.
Read the entire story.
Using germ-killing soap and ointment on all intensive care unit patients can reduce bloodstream infections by up to 44 percent and significantly reduce the presence of methicillin-resistant Staphylococcus aureus (MRSA) in ICUs, according study results published in today’s New England Journal of Medicine.
The REDUCE MRSA trial, funded by the Department of Health and Human Services, was conducted in two stages from 2009-2011. It tested three MRSA prevention strategies and found that using germ-killing soap and ointment on all ICU patients was more effective than other strategies.
“The strategy that proved to be most effective was perhaps the most straightforward: All patients were bathed daily with chlorhexidine antiseptic soap for the duration of their ICU stay and all received mupirocin antibiotic ointment applied in the nose for five days,” said Dr. Mary K. Hayden, associate professor of infectious diseases and pathology at Rush University Medical Center, and one of the co-authors of the study.
Read the entire news release.